| |  Online-Ressource |
|---|
| Verfasst von: | Witzens-Harig, Mathias [VerfasserIn]  |
|---|
| | Klemmer, Jennifer [VerfasserIn] |
|---|
| | Brandt, Julia [VerfasserIn] |
|---|
| | Brants, Elke [VerfasserIn] |
|---|
| | Meißner, Julia [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| | Lengfelder, Eva [VerfasserIn] |
|---|
| | Krämer, Alwin [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| Titel: | Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma |
|---|
| Titelzusatz: | results of the HD2002 prospective multicentre randomized phase III trial |
|---|
| Verf.angabe: | Mathias Witzens-Harig, Axel Benner, Fabienne McClanahan, Jennifer Klemmer, Julia Brandt, Elke Brants, Michael Rieger, Julia Meissner, Manfred Hensel, Kai Neben, Peter Dreger, Eva Lengfelder, Ingo Schmidt-Wolf, Alwin Krämer and Anthony D. Ho |
|---|
| E-Jahr: | 2015 |
|---|
| Jahr: | 9 October 2015 |
|---|
| Umfang: | 10 S. |
|---|
| Fussnoten: | Gesehen am 12.12.2017 |
|---|
| Titel Quelle: | Enthalten in: British journal of haematology |
|---|
| Ort Quelle: | Oxford [u.a.] : Wiley-Blackwell, 1955 |
|---|
| Jahr Quelle: | 2015 |
|---|
| Band/Heft Quelle: | 171(2015), 5, Seite 710-719 |
|---|
| ISSN Quelle: | 1365-2141 |
|---|
| Abstract: | In the multicentre prospective randomized HD2002 trial, rituximab maintenance therapy (375 mg/m2 every 3 months for 2 years) versus observation was evaluated for CD20+ B-cell lymphoma. Out of 321 patients [161 randomized to the treatment group (TG), 160 to the observation group (OG)], 295 data sets were evaluable for statistical analysis. Estimated 5-year relapse-free survival (RFS) was 81% in the TG and 70% in the OG (logrank test, P = 0·047). In the diffuse large B-cell lymphoma (DLBCL) subgroup (n = 152), 5-year RFS was excellent, at 87% in the TG and 84% in the OG (logrank test, P = 0·35). Of note, only in male patients of the DLBCL subgroup was RFS significantly superior in the TG in comparison to the OG (5-year RFS: 88% vs. 74%; logrank test, P = 0·05). Cox regression analysis showed a significant interaction between treatment and gender regarding overall survival (OS) (P = 0·006) and RFS (P = 0·02), with a lower hazard in females than males in the OG [OS: hazard ratio (HR) (female:male) = 0·11; 95% confidence interval (CI) = 0·00-1·03; RFS: HR (female:male) = 0·27; 95% CI = 0·05-0·97], and no significant differences between males and females in the TG. We conclude that Rituximab maintenance therapy improves survival in male patients with DLBCL. |
|---|
| DOI: | doi:10.1111/bjh.13652 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/10.1111/bjh.13652 |
|---|
| | Volltext: http://onlinelibrary.wiley.com.ezproxy.medma.uni-heidelberg.de/doi/10.1111/bjh.13652/abstract |
|---|
| | DOI: https://doi.org/10.1111/bjh.13652 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | diffuse large B-cell lymphoma |
|---|
| | gender differences |
|---|
| | multicentre prospective randomized trial |
|---|
| | rituximab maintenance therapy |
|---|
| K10plus-PPN: | 1566315913 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma / Witzens-Harig, Mathias [VerfasserIn]; 9 October 2015 (Online-Ressource)
